Press Release

Emcure Ref: EPL/CS/SE/0058/2026 Date: July 13, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Press Release Please find enclosed herewith a Press Release titled “Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics; Samit Mehta Leads the Next Phase of Growth”, which shall be released after this intimation. You are requested to take the same on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251 Emcure Consolidates Gennova Ownership; Sharpens Focus on Biologics; Samit Mehta Leads the Next Phase of Growth Pune, July 13, 2026: Emcure Pharmaceuticals Limited (BSE: 544210, NSE: EMCURE) today announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited (“Gennova”), alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company. Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr. Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary. Gennova will be led by Mr. Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms. Commenting on the announcement, Mr. Satish Mehta, Managing Director & CEO, Emcure Pharmaceuticals Limited, said: “We thank Dr. Sanjay Singh for his nearly two decades of exceptional scientific leadership at Gennova. His stewardship has built platforms, products, and a culture that will continue to fulfil Gennova’s mission of transforming healthcare. With this stake acquisition, we simplify Gennova’s ownership, sharpen its strategic focus, and position it under Mr. Samit Mehta’s leadership for its next phase of growth in biologics and biosimilars.” Mr. Samit Mehta, Whole Time Director &CEO, Gennova Biopharmaceuticals Limited, said: “As part of the One Emcure framework, Gennova will continue to anchor the Group's biologics and biosimilars capabilities. Our work will complement Emcure's broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas.” The transaction is not expected to have a material impact on Emcure’s consolidated financials or its capital allocation framework. The Company’s deleveraging trajectory, capex plans and R&D investment plans remain unchanged. Please refer to the Company’s disclosure on BSE / NSE for further details. About Emcure Pharmaceuticals Ltd: Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT March 2026. Emcure is present in 70+ countries globally, including Europe and Canada. Disclaimer: This release contains forward-looking statements based on the Company’s current expectations, which are subject to risks and uncertainties. Actual results may differ materially. The Company undertakes no obligation to update these statements. FOR MORE INFORMATION Media Investors Naveen Soni Saurabh Paliwal corpcomm@emcure.com investor.relations@emcure.com